SEGMENTED INFORMATION

12 Months Ended

Dec. 31, 2023

SEGMENTED INFORMATION

SEGMENTED INFORMATION

NOTE 11 – SEGMENTED INFORMATION

At December 31, 2023, the Company (“BGLC”) operates in the biochemical industry segment through its two Malaysian subsidiaries, MRNA Scientific Malaysia (formerly known as Bionexus Gene Lab Sdn. Bhd.) and Chemrex.

	BioNexus Gene Lab Corp. a Wyoming company
100% owned MRNA Scientific Sdn. Bhd. (formerly “Bionexus Gene Lab Sdn. Bhd.”), a Malaysian company		100% owned Chemrex Corporation Sdn. Bhd., a Malaysian company

For year ended December 31, 2023, segmented revenue and net loss (Currency expressed in United States Dollars (“US$”) are as follows:

	MRNA Scientific
	Malaysia			Chemrex			BGLC			Total
	Year ended December 31, 2023
REVENUE	$	24,219		$	9,746,587		$	-		$	9,770,806
COST OF REVENUE		(19,851	)		(8,421,457	)		-			(8,441,308	)
GROSS PROFIT		4,368			1,325,130			-			1,329,498
OTHER INCOME		19,629			466,407			-			486,036
OPERATING EXPENSES
General and administrative		(245,747	)		(2,019,001	)		(2,144,374	)		(4,409,122	)
FINANCE COSTS		(5,052	)		(8,877	)		-			(13,929	)
LOSS BEFORE TAX		(226,802	)		(236,341	)		(2,144,374	)		(2,607,517	)
Tax expense:
Deferred tax		12,269			5,090			-			17,359
Income tax		(2,613	)		(36,272	)		-			(38,885	)
Total tax expense		9,656			(31,182	)		-			(21,526	)
NET LOSS	$	(217,146	)	$	(267,523	)	$	(2,144,374	)	$	(2,629,043	)

	MRNA Scientific
	Malaysia			Chemrex			BGLC			Total
	Year ended December 31, 2022
REVENUE	$	95,816		$	10,832,891		$	-		$	10,928,707
COST OF REVENUE		(51,465	)		(9,618,213	)		-			(9,669,678	)
GROSS PROFIT		44,351			1,214,678			-			1,259,029
OTHER INCOME		8,830			170,453			-			179,283
OPERATING EXPENSES
General and administrative		(286,753	)		(1,051,855	)		(390,881	)		(1,729,489	)
FINANCE COSTS		(5,657	)		(6,822	)		-			(12,479	)
(LOSS)/PROFIT BEFORE TAX		(239,229	)		326,454			(390,881	)		(303,656	)
Tax expense:
Deferred tax		(1,428	)		(2,470	)		-			(3,898	)
Income tax		-			(48,412	)		-			(48,412	)
Total tax expense		(1,428	)		(50,882	)		-			(52,310	)
NET (LOSS)/PROFIT	$	(240,657	)	$	275,572		$	(390,881	)	$	(355,966	)

	As of December 31, 2023 and 2022
	Total Assets				Total Liabilities
	2023		2022		2023		2022
BGLC & MRNA Scientific	$	4,723,449	$	677,477	$	260,119	$	108,390
Chemrex		6,676,344		8,062,685		1,481,822		1,966,759
TOTAL		11,399,793		8,740,162		1,741,941		2,075,149